CLINICAL RESEARCH
Remnant cholesterol inflammatory index and mortality in cardiovascular-kidney-metabolic syndrome: a national study
More details
Hide details
1
The Second Affiliated Hospital of Xuzhou Medical University, China
Submission date: 2025-12-16
Final revision date: 2025-12-28
Acceptance date: 2026-03-03
Online publication date: 2026-04-08
Corresponding author
Chunmei Qi
The Second Affiliated
Hospital of Xuzhou
Medical University
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Cardiovascular-kidney-metabolic (CKM) syndrome reflects the interconnected progression of metabolic dysfunction, kidney impair-ment, and cardiovascular disease. The remnant cholesterol inflammatory index (RCII), integrating remnant cholesterol and C-reactive protein, may capture combined metabolic-inflammatory stress, but its association with mortality in CKM populations is unclear.
Material and methods:
Using NHANES 1999-2018, we included adults aged ≥ 18 years with complete CKM staging and RCII measurements. All-cause mor-tality was the primary outcome, and cardiovascular mortality the secondary outcome. Kaplan-Meier analysis, Cox models, restricted cubic splines (RCS), and subgroup analyses were performed to evaluate associations between RCII and mortality.
Results:
Among 11,917 CKM participants (median follow-up: 157 months), 2,474 all-cause and 774 cardiovascular deaths occurred. Elevated RCII was associated with increased mortality. In the fully adjusted model, each SD increase in RCII corresponded to a 7% higher risk of all-cause (HR = 1.07, 95% CI: 1.05–1.09) and 8% higher cardiovascular mortality (HR = 1.08, 95% CI: 1.05–1.12) (both p < 0.001). Compared to the lowest RCII quartile (Q1 < 1.61), the highest quartile (Q4 ≥ 13.42) had a 41% higher risk of all-cause (HR = 1.41, 95% CI: 1.24–1.60) and 34% higher cardiovascular mortality (HR = 1.34, 95% CI: 1.06–1.69). RCS analysis revealed significant nonlinear relation-ships, with consistent associations across subgroups and no significant interactions.
Conclusions:
Elevated RCII is strongly and consistently associated with increased all-cause and cardiovascular mortality risks among individuals with CKM. Further studies are warranted to validate its incremental predictive value and to explore targeted interventions for popu-lations with high RCII.
REFERENCES (30)
1.
Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation 2023; 148: 1636-64.
2.
Zhang P, Mo D, Zeng W, Dai H. Association between triglyceride-glucose related indices and all-cause and cardiovascular mortality among the population with cardiovascular-kidney-metabolic syndrome stage 0-3: a cohort study. Cardiovasc Diabetol 2025; 24: 92.
3.
Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020. JAMA 2024; 331: 1858-60.
4.
Theodorakis N, Nikolaou M. From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: pro-posing an expanded framework. Biomolecules 2025;15: 213.
5.
Kittelson KS, Junior AG, Fillmore N, da Silva Gomes R. Cardiovascular-kidney-metabolic syndrome – an integrative review. Prog Cardiovasc Dis 2024; 87: 26-36.
6.
Chen J, Wu Q, Liu H, et al. Predictive value of remnant cholesterol inflammatory index for stroke risk: evidence from the China health and retirement longitudinal study. J Adv Res 2025; 76: 543-52.
7.
Wadström BN, Pedersen KM, Wulff AB, Nordestgaard BG. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur Heart J 2023; 44: 1432-45.
8.
Zhao Y, Zhuang Z, Li Y, et al. Elevated blood remnant cholesterol and triglycerides are causally related to the risks of cardiometabolic mul-timorbidity. Nat Commun 2024; 15: 2451.
9.
Han M, Huang K, Shen C, et al. Discordant high remnant cholesterol with LDL-C increases the risk of stroke: a Chinese Prospective Cohort Study. Stroke 2024; 55: 2066-74.
10.
Tang N, Chen X, Li H, et al. Association of C reactive protein triglyceride glucose index with mortality in coronary heart disease and type 2 diabetes from NHANES data. Sci Rep 2025; 15: 24687.
11.
Ren Y, Xu R, Zhang J, et al. Association between the C-reactive protein-triglyceride-glucose index and endometriosis: a cross-sectional study using data from the National Health and Nutrition Examination Survey, 1996-2006. BMC Womens Health 2025; 25: 13.
12.
Li J, Yan K, Zhu P, et al. Association between multiple inflammatory biomarkers and remnant cholesterol levels in patients with percutane-ous coronary intervention: a large-scale real-world study. Nutr Metab Cardiovasc Dis 2024; 34: 377-86.
13.
Raggi P, Becciu ML, Navarese EP. Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events. Curr Opin Lipidol 2024; 35: 110-6.
14.
Yu Y, Zhang Y, Zhu C, Duan T, Rao Z. Remnant cholesterol inflammatory index, calculated from residual cholesterol to C-reactive protein ra-tio, and stroke outcomes: a retrospective study using the National institutes of health stroke scale and modified Rankin scale. Lipids Health Dis 2025; 24: 228.
15.
Faridi KF, Quispe R, Martin SS, et al. Comparing different assessments of remnant lipoprotein cholesterol: the very large database of lipids. J Clin Lipidol 2019; 13: 634-44.
16.
Solnica B, Sygitowicz G, Sitkiewicz D, et al. 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Associa-tion on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci 2024; 20: 357-74.
17.
Elías-López D, Wadström BN, Vedel-Krogh S, Kobylecki CJ, Nordestgaard BG. Impact of remnant cholesterol on cardiovascular risk in dia-betes. Curr Diab Rep 2024; 24: 290-300.
18.
Doi T, Langsted A, Nordestgaard BG. Remnant cholesterol: should it be a target for prevention of ASCVD?. Curr Atheroscler Rep 2025; 27: 44.
19.
Rizo-Téllez SA, Sekheri M, Filep JG. C-reactive protein: a target for therapy to reduce inflammation. Front Immunol 2023; 14: 1237729.
20.
Melnikov I, Kozlov S, Saburova O, Avtaeva Y, Guria K, Gabbasov Z. Monomeric C-reactive protein in atherosclerotic cardiovascular disease: advances and perspectives. Int J Mol Sci 2023; 24: 2079.
21.
Pastorello Y, Carare RO, Banescu C, Potempa L, Di Napoli M, Slevin M. Monomeric C-reactive protein: a novel biomarker predicting neuro-degenerative disease and vascular dysfunction. Brain Pathol 2023; 33: e13164.
22.
Chapman MJ, Packard CJ, Björnson E, Ginsberg HN, Borén J. Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: what we know and what we need to know. Atherosclerosis 2025; 410: 120529.
23.
Lai T, Liang Y, Guan F, Chen Y, Hu K. Association between remnant cholesterol and arterial stiffness: evidence from NHANES 1999-2018. Nutr Metab Cardiovasc Dis 2025; 35: 104013.
24.
Elías-López D, Kobylecki CJ, Vedel-Krogh S, Doi T, Nordestgaard BG. Association of low-grade inflammation and elevated remnant choles-terol with risk of ASCVD and mortality in impaired renal function. Atherosclerosis 2025; 406: 119241.
25.
Sunayana SRV, Pathade P, Tambe BR. Stimuli-responsive nanocarriers: revolutionizing site-specific drug release. Med Pharm J 2025; 4: 79-99.
26.
Toth PP, Banach M. It is time to address the contribution of cholesterol in all apoB-containing lipoproteins to atherosclerotic cardiovascular disease. Eur Heart J Open 2024; 4: oeae057.
27.
Banach M, Osadnik T, Gierlotka M, et al. Remnant cholesterol and mortality in 37.559 patients from LIPIDOGRAM 2004, 2006 and 2015 studies. Eur Heart J 2024; 45 Suppl. 1: ehae6662827.
28.
Claudel SE, Verma A. Albuminuria in cardiovascular, kidney, and metabolic disorders: a state-of-the-art review. Circulation 2025; 151: 716-32.
29.
Xu H, Liu P, Chen S, Wang G, Wu S, Zhang X. Remnant cholesterol and systemic inflammation as synergistic predictors of cancer risk: a 16-year prospective cohort study. Cancer 2025; 131: e70096.
30.
Hu X, Liu Q, Guo X, et al. The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus. Cardiovasc Dia-betol 2022; 21: 117.